The European consumer health care market will grow more than 150% to$42.5 billion by 2006, forecasts PROMAR International. Of this, the over-the-counter sector will account for around $21 billion, growing 35% in the period.
By 2006, it says, the OTC sector will be operating in a deregulated marketplace, and for an industry hitherto protected from the full impact of market forces, the consequences will be enormous.
- The UK OTC market is Europe's third largest, at a value of around $1.35 billion, and its growth is due in part to UK regulators' liberal and progressive attitude towards OTCs, says a Datamonitor study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze